ArticleAnnals of African medicine2025
Impact of Hepatic Dysfunction on Mortality among Coronavirus Disease 2019 Patients: An Inhospital Observational Study.
Article in Annals of African medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the modern-day pandemic of coronavirus disease 2019 (COVID-19), gastrointestinal (GI) and hepatic manifestations and associated comorbidities are recognized to have poor prognostication in patients with COVID-19. In our present study, we aim to study the frequency of GI manifestations and hepatic dysfunction and to assess for prognostication among hospitalized patients of COVID-19. MATERIALS AND
methodsA retrospective cross-sectional study of hospitalized patients of COVID-19 in a tertiary teaching hospital in South India. Clinical data regarding their GI symptoms and hepatic dysfunction, associated comorbidities, severity of disease, and clinical outcome were recorded.
resultsA total of 1006 patients were included in the study. Severe COVID-19 was seen in 23.3% of the patients, mortality rate of 14.5%. GI manifestations were seen in 17.7% of all, the most common being vomiting (7.1%) and abdominal pain (6.9%). Hepatic dysfunction is seen in 46.5% of COVID-19 patients, which was associated with severity and mortality. However, GI manifestations were not associated with severity and mortality.
conclusionThe occurrence of GI manifestations was common. Hepatic dysfunction was seen more frequently among COVID-19 patients and associated with severity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.